Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Titel:
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Auteur:
Powles, Thomas Plimack, Elizabeth R Soulières, Denis Waddell, Tom Stus, Viktor Gafanov, Rustem Nosov, Dmitry Pouliot, Frédéric Melichar, Bohuslav Vynnychenko, Ihor Azevedo, Sergio J Borchiellini, Delphine McDermott, Raymond S Bedke, Jens Tamada, Satoshi Yin, Lina Chen, Mei Molife, L Rhoda Atkins, Michael B Rini, Brian I